The most recent ad features the same catchy tune, but this time the main character begins her song and dance number at her work ... as a once-daily oral tablet to treat type 2 diabetes in 2014.

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

The fact so many world renowned artists and hit songs came out of the decade speaks to the artistic phenomenon that was taking place at the time. Since the 1980s there has arguably not been ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

Importantly, Boehringer Ingelheim plans to make the KRAS degrader compound ACBI3, freely available for the scientific community through its opnMe® portal, without any strings attached, which ...

Boehringer Ingelheim and Takeda are the only two pharmaceutical groups to be named among the 15 Global Top Employers for 2023, an award dedicated to companies that enrich the workplace environment.

Boehringer Ingelheim is supporting this transformation by partnering with groups working across psychiatric R&D, from small molecules to digital therapeutics. Recognizing the potential to improve ...

The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...

Boehringer Ingelheim was given the opportunity to review ... Kwon BS, Choe J, Chae EJ, Hwang HS, Kim YG, Song JW. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

The molecule ACBI3 developed by multi-disciplinary teams in the laboratory of Professor Alessio Ciulli and Boehringer Ingelheim is based on a class of small molecules called PRoteolysis TArgeting ...